Melox

Meloxicam, the active ingredient in Melox, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an oral tablet for oral use. It reduces inflammation and pain in musculoskeletal disorders and is prescribed for adults with chronic joint conditions.

GNH USA supplies Melox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meloxicam is an NSAID that targets inflammatory pathways in several rheumatic diseases. - Osteoarthritis: alleviates joint pain and improves functional mobility. - Rheumatoid arthritis: reduces synovial inflammation and limits disease progression. - Ankylosing spondylitis: eases spinal stiffness and chronic back pain. - Pain: provides symptomatic relief for moderate to severe musculoskeletal pain.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools occurring intermittently. - Headache: transient cranial discomfort. - Dizziness: sensation of light‑headedness, especially on standing.

Serious or Rare Side Effects: - Gastrointestinal ulcer or bleeding: may present as black stools or abdominal pain. - Cardiovascular events: increased risk of heart attack or stroke in susceptible patients. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before prescribing Melox, clinicians should evaluate patient‑specific risk factors. - Renal impairment: adjust therapy or avoid in severe kidney disease. - Hepatic disease: monitor liver function tests regularly. - Cardiovascular risk: avoid in patients with recent myocardial infarction or uncontrolled hypertension. - Gastrointestinal history: use cautiously in those with prior ulcers or bleeding. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Meloxicam may alter the effect of several co‑administered medicines.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity. - Selective serotonin reuptake inhibitors (SSRIs): heightened hemorrhagic potential.

Moderate Interactions (Monitor Closely):\n- ACE inhibitors or ARBs: possible reduction in renal function. - Diuretics: may enhance nephrotoxic effects, especially in dehydrated patients.